FDA: Hospira recalls three lots of hydromorphone HCL injection
Editor's Note The Food & Drug Administration (FDA) on March 5 announced the recall by Hospira (Lake Forest, Illinois) of three lots of hydromorphone HCL injection, USP Cll 10 mg/mL, 1 mL in 2 mL single dose vials. The recall was initiated because units from these lots may be empty…
FDA issues warning for compounded drugs from Cantrell Drug Company
Editor's Note The Food & Drug Administration (FDA) on March 2 issued a warning for healthcare professionals not to use drug products produced by Cantrell Drug Company (Little Rock, Arkansas), including opioids and other drugs intended for sterile injections. The FDA is concerned about serious deficiencies in Cantrell’s compounding operations,…
CMS extends deadline for eCQM data, EHR incentive program submission
Editor's Note The Centers for Medicare & Medicaid Services (CMS) is notifying eligible hospitals and critical access hospitals that they now have until March 16 to attest for Medicare Electronic Health Record (EHR) Incentive Program requirements for CY 2017 and to submit electronic clinical quality measure (eCQM) data for the…
FDA: Class I recall of certain Medtronic ICDs, CRT-Ds
Editor's Note The Food & Drug Administration (FDA) on February 27 classified the recall by Medtronic of certain Implantable Cardiovert Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) as Class I, the most serious. The recall was initiated because of a defect in the manufacturing process. The defect causes an…
Mayo Clinic’s telemedicine hub reducing ICU mortalities
Editor's Note The Mayo Clinic has built a central telemedicine hub to monitor six ICUs at once, raising the level of care to its patients, the February 21 VCDaily reports. The telemedicine hub operates out of a hospital in Rochester, Minnesota, where a series of interactive video conferencing links provide…
FDA: Hospira recalls four lots of Labetalol Hydrochloride
Editor's Note The Food and Drug Administration (FDA) on February 23 announced the recall by Hospira Inc (Lake Forest, Illinois) of three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL vial (NDC 0409-2267-25), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus (NDC 0409-2267-25). The recall was initiated because…
Joint Commission seeking eCQM success stories
Editor's Note The Joint Commission on February 14 announced that accredited hospitals should start thinking about electronic clinical quality measure (eCQM) success stories to share in the 2018 Pioneers in Quality Proven Practices Collection. Proven Practices was launched last year and is a peer-to-peer sharing of specific practices that an…
Neurosurgical products market poised for growth
Editor's Note Wise Guy Reports predicts the global market for neurosurgical products will see a 10.5% compound annual growth rate through 2023 because of the growing availability of neurosurgical devices and increasing popularity of minimally invasive surgeries, the February 9 Becker’s Spine Review reports. Key players in the market, which…
FDA permits marketing of software to alert providers of potential strokes in patients
Editor's Note The Food & Drug Administration (FDA) on February 13 announced that it is permitting the marketing of clinical decision support software that alerts providers to potential strokes in their patients. The Viz.AI Contact application is designed to analyze computed tomography images of the brain and send a text…
FDA: Class I recall of HeartStart MRx Defibrillator
Editor's Note The Food & Drug Administration (FDA) on February 9 classified the recall by Philips Electronics (Andover, Massachusetts) of its HeartStart MRx Defibrillator as Class I, the most serious. The recall was initiated because of micro cracks in the gas discharge tube that allow internal gasses to escape and…
